title: [Clinical study on qingning oral liquid in treating senile chronic obstructive pulmonary disease with pulmonary hypertension].
abstract: OBJECTIVE
  To evaluate the clinical effect of Qingning Oral Liquid (QNOL) in treating senile chronic obstructive pulmonary disease (COPD) with pulmonary hypertension.
  
  
  METHODS
  Forty patients with mean pulmonary artery pressure (mPAP) more than 2.67 kPa (by impedance rheogram) were divided randomly into two groups. Twenty cases of QNOL group treated by conventional therapy with QNOL cases ml three times a day for 30 days and the other 20 cases treated with conventional therapy alone were taken as control group. Impedance cardiogram and pheopneumogram, blood gas analysis, mean systemic arterial pressure (mSAP), plasma tissue plasminogen activator(tpA) and plasminogen a ctivator inhibitor (PAI) activity were examined before and after treatment.
  
  
  RESULTS
  After treatment, the mPAP of QNOL group lowered for 23.80 +/- 2.31%, the cardiac output, stroke volume and cardiac index of patients were improved, tPA activity elevated and PAI activity decreased. As compared with before treatment and the control group, these changes were significant statistically. The mSAP, PaO2 and PaCO2 were not significantly changed after treatment (P > 0.05). The change of mPAP showed negatively correlated with tPA activity (r = -0.554) and positively correlated with PAI activity (r = 0.608, P < 0.05).
  
  
  CONCLUSIONS
  QNOL has a selective effect on pulmonary hypertension, its mechanism might be correlated to the elevating plasma tPA and the lowering of PAI activity.
authors.affiliation: Department of Internal Medicine, Liyuan Hospital, Wuhan 430077.
authors.forename: R
authors.initials: R
authors.lastname: Yang
authors.forename: J
authors.initials: J
authors.lastname: Yang
authors.forename: Y
authors.initials: Y
authors.lastname: Zeng
mesh_terms: D000368:Aged; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D008173:Lung Diseases, Obstructive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D010992:Plethysmography, Impedance; D010959:Tissue Plasminogen Activator / Q000097:blood; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D004365:Drugs, Chinese Herbal; D017395:Plasminogen Activator Inhibitor 1; D014665:Vasodilator Agents; D010959:Tissue Plasminogen Activator